Research Analysts Set Expectations for COGT Q2 Earnings

Cogent Biosciences, Inc. (NASDAQ:COGT - Free Report) - Equities research analysts at HC Wainwright upped their Q2 2025 earnings per share estimates for Cogent Biosciences in a report released on Tuesday, May 20th. HC Wainwright analyst R. Burns now expects that the technology company will post earnings of ($0.58) per share for the quarter, up from their prior estimate of ($0.66). HC Wainwright has a "Buy" rating and a $12.00 price objective on the stock. The consensus estimate for Cogent Biosciences' current full-year earnings is ($2.42) per share. HC Wainwright also issued estimates for Cogent Biosciences' Q3 2025 earnings at ($0.59) EPS, Q4 2025 earnings at ($0.55) EPS, FY2025 earnings at ($2.24) EPS and FY2026 earnings at ($2.09) EPS.

COGT has been the subject of a number of other reports. Robert W. Baird lowered their price objective on Cogent Biosciences from $8.00 to $7.00 and set a "neutral" rating for the company in a research report on Wednesday, May 7th. Scotiabank assumed coverage on shares of Cogent Biosciences in a research note on Friday, March 7th. They issued a "sector outperform" rating and a $17.00 target price on the stock. Piper Sandler raised shares of Cogent Biosciences to a "strong-buy" rating in a research note on Friday, March 7th. Wedbush restated a "neutral" rating and issued a $11.00 price objective on shares of Cogent Biosciences in a report on Tuesday, February 25th. Finally, Needham & Company LLC reaffirmed a "hold" rating on shares of Cogent Biosciences in a report on Wednesday, February 26th. Three research analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $14.00.

Cogent Biosciences Stock Performance

Shares of NASDAQ:COGT opened at $4.98 on Thursday. The company's fifty day moving average is $5.28 and its 200-day moving average is $7.38. Cogent Biosciences has a 52 week low of $3.72 and a 52 week high of $12.61. The company has a market capitalization of $567.00 million, a PE ratio of -2.01 and a beta of 1.91.

Cogent Biosciences (NASDAQ:COGT - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The technology company reported ($0.52) EPS for the quarter, beating the consensus estimate of ($0.56) by $0.04.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the company. CWM LLC boosted its position in shares of Cogent Biosciences by 11,869.9% during the first quarter. CWM LLC now owns 8,738 shares of the technology company's stock worth $52,000 after purchasing an additional 8,665 shares in the last quarter. Schonfeld Strategic Advisors LLC bought a new stake in shares of Cogent Biosciences in the 4th quarter valued at $78,000. Hsbc Holdings PLC acquired a new stake in Cogent Biosciences during the 4th quarter worth $81,000. KLP Kapitalforvaltning AS bought a new position in Cogent Biosciences during the fourth quarter worth about $88,000. Finally, E Fund Management Co. Ltd. acquired a new position in Cogent Biosciences in the fourth quarter valued at about $89,000.

About Cogent Biosciences

Cogent Biosciences, Inc, a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.